REGN Stock: Regeneron Pharmaceuticals, Inc. Stock Price, Analysis & Insights
Get live regn stock price $580.70, comprehensive Regeneron Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time regn stock data and investment insights.
Company Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Company Information
- CEO
- Leonard S. Schleifer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15158
Contact Information
- Website
- https://www.regeneron.com
- Address
- 777 Old Saw Mill River Road
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 60.49B market capitalization
- Trading Volume: 572.98K shares traded today
- Price Range: 52-week range of $476.49 - $1192.54
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 60.49B, the company represents a significant player in its market. The stock is currently trading at $580.70 with a positivedaily change of 0.19%.
The company's 15158 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 14.63, beta of 0.33, and 52-week price range from $476.49 to $1192.54when evaluating investment opportunities.
Why Invest in Regeneron Pharmaceuticals, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Leonard S. Schleifer
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.